Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Oct 9;79(15):1556-62.
doi: 10.1212/WNL.0b013e31826e25df. Epub 2012 Sep 12.

SQSTM1 mutations in frontotemporal lobar degeneration and amyotrophic lateral sclerosis

Elisa Rubino  1 , Innocenzo Rainero, Adriano Chiò, Ekaterina Rogaeva, Daniela Galimberti, Pierpaola Fenoglio, Yakov Grinberg, Giancarlo Isaia, Andrea Calvo, Salvatore Gentile, Amalia Cecilia Bruni, Peter Henry St George-Hyslop, Elio Scarpini, Salvatore Gallone, Lorenzo Pinessi; TODEM Study Group
Collaborators, Affiliations

SQSTM1 mutations in frontotemporal lobar degeneration and amyotrophic lateral sclerosis

Elisa Rubino et al. Neurology. .

Abstract

Objective: There is increasing evidence that common genetic risk factors underlie frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS). Recently, mutations in the sequestosome 1 (SQSTM1) gene, which encodes p62 protein, have been reported in patients with ALS. P62 is a multifunctional adapter protein mainly involved in selective autophagy, oxidative stress response, and cell signaling pathways. The purpose of our study was to evaluate the frequency of SQSTM1 mutations in a dataset of unrelated patients with FTLD or ALS, in comparison with healthy controls and patients with Paget disease of bone (PDB).

Methods: Promoter region and all exons of SQSTM1 were sequenced in a large group of subjects, including patients with FTLD or ALS, healthy controls, and patients with PDB. The clinical characteristics of patients with FTLD or ALS with gene mutations were examined.

Results: We identified 6 missense mutations in the coding region of SQSTM1 in patients with either FTLD or ALS, none of which were found in healthy controls or patients with PDB. In silico analysis suggested a pathogenetic role for these mutations. Furthermore, 7 novel noncoding SQSTM1 variants were found in patients with FTLD and patients with ALS, including 4 variations in the promoter region.

Conclusions: SQSTM1 mutations are present in patients with FTLD and patients with ALS. Additional studies are warranted in order to better investigate the role of p62 in the pathogenesis of both FTLD and ALS.

PubMed Disclaimer

Comment in

References

    1. Mackenzie IR, Feldman HH. Ubiquitin immunohistochemistry suggests classic motor neuron disease, motor neuron disease with dementia, and frontotemporal dementia of the motor neuron disease type represent a clinicopathologic spectrum. J Neuropathol Exp Neurol 2005; 64: 730– 739. - PubMed
    1. Lillo P, Hodges JR. Frontotemporal dementia and motor neuron disease: overlapping clinic-pathological disorders. J Clin Neurosci 2009; 16: 1131– 1135. - PubMed
    1. Burrell JR, Kiernan MC, Vucic S, Hodges JR. Motor neuron dysfunction in frontotemporal dementia. Brain 2011; 134: 2582– 2594. - PubMed
    1. Kwong LK, Neumann M, Sampathu DM, Lee VM, Trojanowski JQ. TDP-43 proteinopathy: the neuropathology underlying major forms of sporadic and familial frontotemporal lobar degeneration and motor neuron disease. Acta Neuropathol 2007; 114: 63– 70. - PubMed
    1. Parkinson N, Ince PG, Smith MO, et al. ALS phenotypes with mutations in CHMP2B (charged multivesicular body protein 2B). Neurology 2006; 67: 1074– 1077. - PubMed

Publication types

Substances